首頁 > 市場調查報告書 > 製藥

再生醫學細胞療法

市場調查報告書

商品編碼

1593508

細胞和基因治療市場規模、佔有率和成長分析（按治療類型、治療層級、遞送方法、最終用戶和地區）：產業預測（2024-2031）

Cell and Gene Therapy Market Size, Share, Growth Analysis, By Therapy Type (Cell Therapy, Gene Therapy), By Therapeutic class (Cardiovascular Disease, Cancer), By Delivery Method, By End-Users, By Region - Industry Forecast 2024-2031

出版日期: 2024年11月13日 | 出版商:

SkyQuest | 英文 194 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球細胞和基因治療市場規模預計為177億美元，從2023年的209.7億美元擴大到2031年的815.5億美元，預計在預測期內（2024-2031年）成長 2018 年複合年成長率。為18.50%）。

由於基因工程的進步和細胞研究投資的增加，預計未來幾年細胞和基因治療市場將顯著成長。創新細胞和基因療法在多種疾病中的廣泛應用正在為產業相關人員創造新的機會。對加強患者照護的關注，加上對先進治療方案的需求不斷增加以及慢性病的流行，是推動市場擴張的關鍵因素。此外，個人化醫療的趨勢和突破性治療方法的監管核准率不斷提高，進一步為該領域的新業務前景鋪平了道路。然而，與先進治療相關的挑戰，例如高成本、有限的報銷選擇以及獲得新療法的機會有限，也可能阻礙創新解決方案的廣泛採用。解決這些限制對於充分發揮細胞和基因治療市場的潛力並將其定位為未來醫學進步的關鍵領域至關重要。總體而言，技術創新和不斷變化的患者需求相結合，表明細胞和基因治療市場前景光明，使其成為醫療產業投資和發展的有吸引力的領域。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲
中東和非洲 (MEA)
- 波灣合作理事會(GCC) 國家
- 南非
- 其他中東/非洲

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

Alnylam 製藥公司（美國）
安進公司（美國）
百健公司（美國）
CORESTEM Inc.（美國）
Helixsmith Co. Ltd.（韓國）
JCR 製藥有限公司（日本）
Kolon TissueGene Inc.（韓國）
諾華公司（瑞士）
輝瑞公司（美國）
吉利德科學公司（美國）
Sangamo Therapeutics, Inc.（美國）
藍鳥生物公司（美國）
Zymeworks Inc.（加拿大）
CRISPR Therapeutics AG（瑞士）
Celyad Oncology SA（比利時）
Atara Biotherapeutics, Inc.（美國）
Athenex, Inc.（美國）
百時美施貴寶（美國）
協和麒麟（日本）
賽諾菲（法國）

簡介目錄

Product Code: SQMIG35G2300

Global Cell and Gene Therapy Market size was valued at USD 17.7 billion in 2022 and is poised to grow from USD 20.97 billion in 2023 to USD 81.55 billion by 2031, growing at a CAGR of 18.50% during the forecast period (2024-2031).

The cell and gene therapy market is set to experience significant growth in the coming years, driven by advancements in genetic engineering and increased investments in cellular research. The expanding application of innovative cell and gene therapies for a range of diseases presents new opportunities for industry players. A heightened focus on enhancing patient care, coupled with the rising demand for advanced treatment options and the growing prevalence of chronic diseases, are pivotal factors propelling market expansion. Additionally, the trend towards personalized medicine and the increasing rate of regulatory approvals for groundbreaking therapies further pave the way for new business prospects within this sector. However, the market does face challenges, namely the high costs associated with advanced therapies, limited reimbursement options, and restricted access to novel treatments, which may hinder broader adoption of these innovative solutions. Addressing these constraints will be essential for realizing the full potential of the cell and gene therapy market, positioning it as a key area for future healthcare advancements. Overall, the combination of technological innovation and evolving patient needs suggests a promising trajectory for the cell and gene therapy landscape, making it an appealing area for investment and development in the healthcare industry.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cell And Gene Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cell And Gene Therapy Market Segmental Analysis

Global Cell and Gene Therapy Market is segmented by Therapy Type, Therapeutic class, Delivery Method, End-Users, and region. Based on Therapy Type, the market is segmented into Cell Therapy, Stem Cells (T Cells, Dendritic Cells, NK Cells, Tumor Cells), Gene Therapy (Gene Silencing, Cell Replacement, Gene Augmentation, Other Therapies). Based on Therapeutic class, the market is segmented into Cardiovascular Disease, Cancer, Genetic Disorder, Rare Diseases, Oncology, Hematology, Ophthalmology, Infectious Disease, Neurological Disorders, and Others. Based on Delivery Method, the market is segmented into In Vivo, and Ex Vivo. Based on End-Users, the market is segmented into Hospitals, Cancer Care Centers, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Cell And Gene Therapy Market

Advancements in gene technologies are a significant market driver for the Global Cell and Gene Therapy market. These innovations, including CRISPR, recombinant DNA technology, and next-generation sequencing, have enhanced the precision and efficacy of gene editing and modification, paving the way for targeted therapies. With the increasing prevalence of genetic disorders, cancer, and rare diseases, these advanced technologies facilitate the development of more personalized and effective treatment options. Furthermore, ongoing research and investment in biopharmaceuticals are accelerating the translation of these technologies from the lab to clinical applications, propelling market growth and attracting both public and private funding.

Restraints in the Global Cell And Gene Therapy Market

One of the significant market restraints for the global cell and gene therapy market is the prohibitively high costs associated with these treatments. The complex and specialized nature of developing gene and cell therapies often results in substantial research and development expenditures, which are subsequently passed on to patients. This financial barrier limits access for a considerable segment of the population, potentially leading to disparities in treatment availability. Additionally, the high price tag poses challenges for healthcare providers and payers in terms of reimbursement and health insurance coverage, ultimately hindering market growth and patient adoption of these innovative therapies.

Market Trends of the Global Cell And Gene Therapy Market

The Global Cell and Gene Therapy market is witnessing a notable trend towards the increasing demand for combination therapies, which integrate the advantages of both gene and cell therapies. This trend is driven by a growing recognition of the high efficacy these integrated approaches offer in treating complex and multifaceted medical conditions. As healthcare professionals and patients alike seek more effective treatment options, cell and gene therapy companies are urged to innovate and develop novel combination therapies. This focus aims to enhance patient outcomes across a variety of disease indications, thereby positioning companies favorably within a rapidly evolving biopharmaceutical landscape.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Value Chain Analysis
Ecosystem of the Market
Case study Analysis
Regulatory Landscape
Top Investment Analysis
Key Success Factor
Degree of Competition
Market Attractiveness Index, 2023

Cell and Gene Therapy Market by Therapy Type

Market Overview
Cell Therapy
- Stem Cells
- T Cells
- Dendritic Cells
- NK Cells
- Tumor Cells
Gene Therapy
- Gene Silencing
- Cell Replacement
- Gene Augmentation
- Other Therapies

Cell and Gene Therapy Market by Therapeutic class

Market Overview
Cardiovascular Disease
Cancer
Genetic Disorder
Rare Diseases
Oncology
Hematology
Ophthalmology
Infectious Disease
Neurological Disorders
Others

Cell and Gene Therapy Market by Delivery Method

Market Overview
In Vivo
Ex Vivo

Cell and Gene Therapy Market by End-Users

Market Overview
Hospitals
Cancer Care Centers
Others

Cell and Gene Therapy Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Alnylam Pharmaceuticals Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CORESTEM Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Helixmith Co. Ltd. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
JCR Pharmaceuticals Co. Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kolon TissueGene Inc. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sangamo Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bluebird Bio, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zymeworks Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CRISPR Therapeutics AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celyad Oncology SA (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Atara Biotherapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Athenex, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kyowa Kirin (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments